carbidopa(redirected from Levocarb CR)
Also found in: Dictionary.
Related to Levocarb CR: Levodopa-carbidopa, Sinemet, Sinemet cr
an inhibitor of the decarboxylation of levodopa in peripheral tissues; it does not cross the blood-brain barrier and is used in combination with levodopa to control the symptoms of parkinson's disease. In the presence of carbidopa, levodopa enters the brain in larger quantities, thus avoiding the need for excessively high doses of levodopa.
A dopa decarboxylase inhibitor that does not enter the brain used in conjunction with levodopa in the treatment of Parkinson disease to reduce L-dopa dosage and mitigate side effects.
carbidopa/car·bi·do·pa/ (kahr″bĭ-do´pah) an inhibitor of decarboxylation of levodopa in extracerebral tissues, used in combination with levodopa as an antiparkinsonian agent.
A drug, C10H14N2O4, that increases the availability of L-dopa to the brain and is administered with L-dopa to treat Parkinson's disease.
a dopa decarboxylase inhibitor that cannot cross the blood-brain barrier.
indication It is prescribed in combination with levodopa in the treatment of idiopathic Parkinson's disease because it inhibits the degradation of levodopa in the periphery, thereby permitting a larger percentage of orally administrated doses to enter the brain.
contraindications Glaucoma, hypertension, use of a monoamine oxidase inhibitor within the past 14 days, or known hypersensitivity to this drug prohibits its use.
adverse effects Among the most serious adverse reactions are GI bleeding, cardiac irregularity, hemolytic anemia, tardive dyskinesia, mental depression, blurred vision, and activation of malignant melanoma.
A dopa decarboxylase inhibitor that does not enter the brain used in conjunction with levodopa in the treatment of parkinsonism to reduce L-dopa dosage and mitigate side effects.